Insider Selling: Novavax, Inc. (NVAX) Director Sells 175,000 Shares of Stock

Novavax, Inc. (NASDAQ:NVAX) Director James F. Young sold 175,000 shares of the company’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $1.06, for a total value of $185,500.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Shares of Novavax, Inc. (NVAX) traded up 4.76% during trading on Friday, reaching $1.10. The company’s stock had a trading volume of 7,913,802 shares. The stock’s 50 day moving average price is $1.09 and its 200-day moving average price is $1.12. Novavax, Inc. has a 12 month low of $0.73 and a 12 month high of $8.49. The firm’s market cap is $318.89 million.

Novavax (NASDAQ:NVAX) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.16). Novavax had a negative net margin of 1,006.00% and a negative return on equity of 787.38%. The firm had revenue of $6.70 million for the quarter, compared to analysts’ expectations of $6.15 million. During the same quarter last year, the firm earned ($0.29) EPS. The company’s quarterly revenue was up 168.0% compared to the same quarter last year. Equities analysts predict that Novavax, Inc. will post ($0.62) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://transcriptdaily.com/2017/09/02/insider-selling-novavax-inc-nvax-director-sells-175000-shares-of-stock.html.

Several institutional investors have recently bought and sold shares of the company. Teachers Advisors LLC boosted its position in Novavax by 4.2% in the fourth quarter. Teachers Advisors LLC now owns 455,686 shares of the biopharmaceutical company’s stock valued at $574,000 after buying an additional 18,519 shares in the last quarter. Wells Fargo & Company MN boosted its position in Novavax by 2.7% in the first quarter. Wells Fargo & Company MN now owns 343,714 shares of the biopharmaceutical company’s stock valued at $440,000 after buying an additional 8,966 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in Novavax during the first quarter valued at approximately $157,000. Bank of New York Mellon Corp boosted its position in Novavax by 0.9% in the first quarter. Bank of New York Mellon Corp now owns 1,215,100 shares of the biopharmaceutical company’s stock valued at $1,555,000 after buying an additional 10,347 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Novavax by 41.9% in the first quarter. JPMorgan Chase & Co. now owns 3,708,105 shares of the biopharmaceutical company’s stock valued at $4,746,000 after buying an additional 1,095,388 shares in the last quarter. 45.16% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms recently issued reports on NVAX. Zacks Investment Research lowered Novavax from a “buy” rating to a “hold” rating in a report on Saturday, August 19th. BidaskClub lowered Novavax from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Ladenburg Thalmann Financial Services upgraded Novavax from a “neutral” rating to a “buy” rating and set a $1.60 target price on the stock in a report on Wednesday, August 9th. Chardan Capital reiterated a “neutral” rating and set a $1.50 target price on shares of Novavax in a report on Thursday, July 27th. Finally, Piper Jaffray Companies reiterated a “hold” rating and set a $1.50 target price on shares of Novavax in a report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $2.67.

About Novavax

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Insider Buying and Selling by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply